Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it
works compared to control cleansing in preventing central line associated bloodstream
infection and acquisition of multi-drug resistant organisms in younger patients with cancer
or undergoing donor stem cell transplant. Chlorhexidine gluconate may help reduce
bloodstream infections and bacterial infections associated with the central line.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society